MIRA INFORM REPORT
|
Report Date : |
07.03.2012 |
IDENTIFICATION DETAILS
|
Name : |
UNITMA CO., LTD. |
|
|
|
|
Registered Office : |
224-8, Jamsilbon-dong, Songpa-gu, Seoul, Korea, 3rd Fl., Cheongmyeong
Bldg., Zip Code 138-863 |
|
|
|
|
Country : |
South korea |
|
|
|
|
Financials (as on) : |
31.12.2008 |
|
|
|
|
Date of Incorporation : |
13.03.2006 |
|
|
|
|
Com. Reg. No.: |
215-86-82985 |
|
|
|
|
Legal Form : |
Co., Ltd by Shares |
|
|
|
|
Line of Business : |
Manufacture of Other Medical and Surgical Equipment and Orthopedic
Appliances |
|
|
|
|
No. of Employees
: |
10 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment
Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
South Korea |
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company
Name |
UNITMA CO., LTD. (Korean Company
Name : “유니트마(주)”) |
|
Registered Address |
224-8, Jamsilbon-dong, Songpa-gu, Seoul,
Korea |
|
Building |
3rd Fl., Cheongmyeong Bldg. |
|
Zip Code |
138-863 |
|
Tel |
+82-2-420-0070 |
|
Fax |
+82-2-420-9797 |
|
E-mail |
|
|
Website |
|
|
Trading Address |
3rd Fl., Cheongmyeong Bldg., 224-8,
Jamsilbon-dong, Songpa-gu, Seoul, Korea |
|
Tel |
+82-2-420-0070 |
|
Fax |
+82-2-420-9797 |
|
Type |
Export |
|
Industry |
Manufacture of Other Medical and Surgical Equipment and Orthopedic
Appliances n.e.c. |
|
Main Business |
Manual Tissue Microarrayer, Automated Tissue Microarrayer, Insulin Pump,
Recipient Block, Carbon Film Heater |
|
Established (mm/dd/yyyy) |
03/13/2006 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Enteral feeding infusion pumps(42231501) |
|
Sell |
Clinical and diagnostic analyzers and
accessories and supplies(41115800) |
|
Name |
Lee Young-Do |
|
Address |
Suite 602, 307-2, Jamsil-dong,
Songpa-gu, Seoul, Korea |
|
Date of Birth |
02/16/1959 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
300,000,000 |
|
Employees |
10 |
|
Formation |
Co., Ltd by Shares |
|
Bank Details |
N/A |
|
Corporate Registered No. |
110111-3417890 |
|
Business Registered No. |
215-86-82985 |
|
Permit & Licenses |
08/2007 ISO 9001 02/2008 CE Mark 04/2008 CE Mark 05/2008 UL Mark |
|
Shareholder Position |
N/A |
|
Company History |
03/13/2006 Incorporated as the present name 04/04/2006 Increased the authorized shares
to 2,400,000 shares from 400,000 shares 04/04/2006 Increased capital to 300,000,000
KRW from 58,823,500 KRW 02/06/2007 Designated as a Venture Business 02/06/2008 Designated as a Venture Business
again 04/2009 Designated as an INNO-BIZ Company 02/2010 Designated as a Venture Business
again 06/2010 Designated as a Promising SME |
|
|
|
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Lee Young-Do |
Male |
Korean |
03/13/2009 |
|
Director |
Mr. |
Jung Hyung-Jae |
Male |
Korean |
03/13/2009 |
|
Director |
M/S. |
Shin Joo-Yeon |
Female |
Korean |
03/13/2009 |
|
Auditor |
M/S. |
Bum Hyang-Ok |
Female |
Korean |
03/13/2009 |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
1,500,000,000 |
|
|
|
|
2009 |
|
|
|
|
2008 |
421,000,000 |
488,000,000 |
93,000,000 |
|
2007 |
480,000,000 |
|
|
|
2006 |
220,000,000 |
|
|
The financials are
not available, and the Subject Company does not have any obligations to release
its financials to the public.
|
Authorized Capital(KRW) |
1,200,000,000 |
|
Paid-Up Capital(KRW) |
300,000,000 |
|
Total Issued Shares |
600,000 |
Balance
Sheet
|
|||
|
Unit : Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Total Assets |
|
|
488,000,000 |
|
Current Assets |
|
|
202,000,000 |
|
-Quick Assets |
|
|
122,000,000 |
|
-Inventories |
|
|
80,000,000 |
|
Fixed Assets |
|
|
286,000,000 |
|
-Investment |
|
|
97,000,000 |
|
-Tangibles |
|
|
169,000,000 |
|
-Intangibles |
|
|
|
|
Total Liabilities |
|
|
201,000,000 |
|
Current Liabilities |
|
|
201,000,000 |
|
Fixed Liabilities |
|
|
|
|
Capital Stock |
|
|
300,000,000 |
|
Capital Surplus |
|
|
|
|
Profit Surplus |
|
|
5,000,000 |
|
Capital Adjustment |
|
|
-18,000,000 |
|
Total Equity |
|
|
287,000,000 |
|
Liab. & Shareholder’s Equity |
|
|
488,000,000 |
Income
Statement
|
|||
|
Unit : Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Sales |
|
|
421,000,000 |
|
Cost of Sold Goods |
|
|
185,000,000 |
|
Gross Profit |
|
|
236,000,000 |
|
Selling & Admin. Expenses |
|
|
144,000,000 |
|
Operating Income |
|
|
92,000,000 |
|
Non-Operating Income |
|
|
26,000,000 |
|
Non-Operating Expenses |
|
|
25,000,000 |
|
Income Before Taxes |
|
|
93,000,000 |
|
Income Taxes Expenses |
|
|
|
|
Net Income |
|
|
93,000,000 |
|
Main Products & Services |
Manual Tissue Microarrayer, Automated Tissue Microarrayer, Insulin
Pump, Recipient Block, Carbon Film Heater |
|
Competitors |
KOREA BONE BANK CO., LTD. RM. 402, NAMSUNG PLAZA(ACE 9-CHA), 345-30, GASAN-DONG,
GEUMCHEON-GU, SEOUL, KOREA TEL:+82-2-2104-0475 FAX:+82-2-2104-0478 SOLCO BIOMEDICAL CO., LTD. 34-6, GEUMAM-RI, SEOTAN-MYEON,
PYEONGTAEK-SI, GYEONGGI-DO, KOREA TEL:+82-31-664-4101 FAX:+82-31-663-6520 DIO MEDICAL CO., LTD. RM. 103, MEGA CENTER, SKN TECHNO PARK,
190-1, SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO, KOREA TEL:+82-31-776-3690 FAX:+82-31-776-3691 |
(Activity & Markets)
The Subject exports
to Italy, Turkey, Pakistan, India, Vietnam, China and Taiwan.
Not Available.
---
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.50.03 |
|
UK Pound |
1 |
Rs.79.32 |
|
Euro |
1 |
Rs.66.02 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.